Cu64/67 is owned by Clarity (NSW based). SAR-bisPSMA - Next-Generation, Highly Targeted Prostate Cancer Theranostic - Clarity (claritypharmaceuticals.com)
They are not listed, hadn't heard they were planning for ASX listing.
Cu64 has theoretical advantages. With a 12h half life, you can do serial imaging - you get an idea of disease sites the injection gets to after a few hours, then a day later you can see if those sites retained the tracer and potentially even stretch it out to 2 days.
This is useful for estimating dosimetry and the actual radiation dose delivered to sites of disease.
With Ga68 (~1h half life), you cannot assess for retention beyond 3-4h, so even if a disease site takes up the tracer very strongly, it might dissociate after 8 hours and you'd never know. So if you were to administer Lu-177 bound to the ligand, there would only be treatment at the disease site for a short while (ie. may not work).
Same with Zr89 btw (TLX using this for TLX250 cdx, even longer half life at 78h.)
hope that makes senes
- Forums
- ASX - By Stock
- TLX
- Competition
Competition, page-25
-
- There are more pages in this discussion • 230 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.93 |
Change
0.540(2.78%) |
Mkt cap ! $6.669B |
Open | High | Low | Value | Volume |
$19.49 | $20.00 | $18.97 | $53.42M | 2.706M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 601 | $19.92 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.93 | 2099 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1124 | 19.800 |
2 | 17613 | 19.780 |
1 | 2201 | 19.760 |
1 | 6683 | 19.740 |
2 | 9683 | 19.690 |
Price($) | Vol. | No. |
---|---|---|
19.930 | 1498 | 1 |
19.940 | 250 | 1 |
19.970 | 6683 | 1 |
19.980 | 500 | 1 |
19.990 | 2000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |